Search

Your search keyword '"Nitz U"' showing total 503 results
Start Over Author "Nitz U"
503 results on '"Nitz U"'

1. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Author

Martín, M., Stecklein, S.R., Gluz, O., Villacampa, G., Monte-Millán, M., Nitz, U., Cobo, S., Christgen, M., Brasó-Maristany, F., Álvarez, E.L., Echavarría, I., Conte, B., Kuemmel, S., Bueno-Muiño, C., Jerez, Y., Kates, R., Cebollero, M., Kolberg-Liedtke, C., Bueno, O., García-Saenz, J.Á., Moreno, F., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Wuerstleins, R., Graeser, M., zu Eulenburg, C., Kreipe, H.H., Gómez, H., Massarrah, T., Herrero, B., Paré, L., Bohn, U., López-Tarruella, S., Vivancos, A., Sanfeliu, E., Parker, J.S., Perou, C.M., Villagrasa, P., Prat, A., Sharma, P., and Harbeck, N.

Published
2024
Full Text
View/download PDF

2. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Author

Gluz, O., Kuemmel, S., Nitz, U., Braun, M., Lüdtke-Heckenkamp, K., von Schumann, R., Darsow, M., Forstbauer, H., Potenberg, J., Uleer, C., Grischke, E.M., Aktas, B., Schumacher, C., zu Eulenburg, C., Kates, R., Jóźwiak, K., Graeser, M., Wuerstlein, R., Baehner, R., Christgen, M., Kreipe, H.H., and Harbeck, N.

Published
2023
Full Text
View/download PDF

3. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

Author

Möbus, V, Jackisch, C, Lück, HJ, du Bois, A, Thomssen, C, Kuhn, W, Nitz, U, Schneeweiss, A, Huober, J, Harbeck, N, von Minckwitz, G, Runnebaum, IB, Hinke, A, Konecny, GE, Untch, M, Kurbacher, C, and Group, AGO Breast Study

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Disease-Free Survival, Dose-Response Relationship, Drug, Epirubicin, Female, Humans, Lymphatic Metastasis, Middle Aged, Paclitaxel, Risk Factors, Survival Rate, high-risk early breast cancer, dose-dense, intense dose-dense, AGO Breast Study Group, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundPrimary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) trial compared intense dose-dense (idd) adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk BC patients. Here we report the final, 10-year follow-up analysis.Patients and methodsEnrolment took place between December 1998 and April 2003. A total of 1284 patients with 4 or more involved axillary lymph nodes were randomly assigned to receive 3 courses each of idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC → P) q3w. Event-free survival (EFS) was the primary end point.ResultsA total of 658 patients were assigned to receive iddEPC and 626 patients were assigned to receive EC → P. The median duration of follow-up was 122 months. EFS was 47% (95% CI 43% to 52%) in the standard group and 56% (95% CI 52% to 60%) in the iddEPC group [hazard ratio (HR) 0.74, 95% CI 0.63-0.87; log-rank P = 0.00014, one-sided]. This benefit was independent of menopausal, hormone receptor or HER2 status. Ten-year overall survival (OS) was 59% (95% CI 55% to 63%) for patients in the standard group and 69% (95% CI 65% to 73%) for patients in the iddEPC group (HR = 0.72, 95% CI 0.60-0.87; log-rank P = 0.0007, two-sided). Nine versus two cases of secondary myeloid leukemia/myelodysplastic syndrome were observed in the iddEPC and the EC → P arm, respectively.ConclusionThe previously reported OS benefit of iddEPC in comparison to conventionally dosed EC → P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up.

Published
2018

5. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Author

Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., and Kuhn, W.

Published
2014
Full Text
View/download PDF

8. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017)

Author

Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N., Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., and Harbeck, N.

Published
2022

9. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression†

Author

Nitz, U, Gluz, O, Huober, J, Kreipe, H H, Kates, R E, Hartmann, A, Erber, R, Moustafa, Z, Scholz, M, Lisboa, B, Mohrmann, S, Möbus, V, Augustin, D, Hoffmann, G, Weiss, E, Böhmer, S, Kreienberg, R, Du Bois, A, Sattler, D, Thomssen, C, Kiechle, M, Jänicke, F, Wallwiener, D, Harbeck, N, and Kuhn, W

Published
2017
Full Text
View/download PDF

10. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Author

Nitz, U A, Gluz, O, Christgen, M, Grischke, E -M, Augustin, D, Kuemmel, S, Braun, M, Potenberg, J, Kohls, A, Krauss, K, Stefek, A, Schumacher, C, Forstbauer, H, Reimer, T, Fischer, H, Liedtke, C, Wuerstlein, R, Schumacher, J, Kates, R, Kreipe, H, and Harbeck, N

Published
2017
Full Text
View/download PDF

11. Entwicklung der Therapie des Ovarialkarzinoms

Author

für die AGO-Studiengruppe Ovarialkarzinom, du Bois, A., Lück, H. J., Meier, W., Möbus, V., Warm, M., Costa, S., Richter, B., Schröder, W., Bauknecht, Th., Olbricht, S., Nitz, U., Jackisch, Ch., Bunjes, D., Opri, F., Berdel, W. E., Wallwiener, D., Haas, R., Kuhn, W., von Schilling, C., Thomssen, C., Hossfeld, D. K., Frickhofen, N., Kreienberg, R., Quaas, J., Pfisterer, J., Meerpohl, H. G., Berg, Dietrich, editor, Diedrich, Klaus, editor, and Rauskolb, Rüdiger, editor

Published
2000
Full Text
View/download PDF

17. LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

Author

Harbeck, N., primary, Nitz, U., additional, Christgen, M., additional, Kuemmel, S., additional, Braun, M., additional, Biehl, C.M., additional, Schumacher, C., additional, Malter, W., additional, Aktas, B., additional, Forstbauer, H., additional, Tio, J., additional, Grischke, E-M., additional, Kolberg-Liedtke, C., additional, de Haas, S., additional, Deurloo, R.J., additional, Kates, R.E., additional, Eulenburg zu, C., additional, Wuerstlein, R., additional, Kreipe, H., additional, and Gluz, O., additional

Published
2021
Full Text
View/download PDF

21. Pathologische Komplettremissionsrate und Überleben von Patientinnen mit BRCA-assoziiertem triple-negativen Brustkrebs nach 12 Wochen anthrazyklinfreier neoadjuvanter Chemotherapie: Ergebnisse der WSG-ADAPT TN Studie (NCT01815242)

Author

Richters, LK, additional, Gluz, O, additional, Weber-Lassalle, N, additional, Christgen, M, additional, Haverkamp, H, additional, Kuemmel, S, additional, Kayali, M, additional, Kates, R, additional, Grischke, E-M, additional, Braun, M, additional, Warm, M, additional, Wuerstlein, R, additional, Ernst, C, additional, Graeser, M, additional, Hauke, J, additional, Nitz, U, additional, Kreipe, HH, additional, Schmutzler, RK, additional, Harbeck, N, additional, and Hahnen, E, additional

Published
2021
Full Text
View/download PDF

22. Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer : WSG ADAPT TP trial

Author

Harbeck, Nadia, Nitz, U., Christgen, Matthias, Kümmel, Sherko, Braun, Michael S., Biehl, C.M., Schumacher, Claudia, Malter, Wolfram, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva Maria, Kolberg-Liedtke, Cornelia, de Haas, Sanne Lysbet, Deurloo, Regula J., Kates, R.E., Eulenburg zu, Christine, Wuerstlein, Rachel, Kreipe, Hans Heinrich, and Gluz, Oleg

Subjects
Medizin
Published
2021

23. Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

Author

Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H., Gluz, O., Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H., and Gluz, O.

Published
2021

28. LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial

Author

Graeser, M., primary, Gluz, O., additional, Biehl, C., additional, Ulbrich-Gebauer, D., additional, Palatty, J., additional, Christgen, M., additional, Kuemmel, S., additional, Grischke, E-M., additional, Augustin, D., additional, Braun, M., additional, Potenberg, J., additional, Wuerstlein, R., additional, Eulenburg, C., additional, Kates, R., additional, Kolberg-Liedtke, C., additional, Feuerhake, F., additional, Kreipe, H., additional, Nitz, U., additional, and Harbeck, N., additional

Published
2021
Full Text
View/download PDF

29. De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results

Author

Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R., Kreipe, H., Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R., and Kreipe, H.

Published
2020

30. High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes

Author

Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R., Kreipe, H., Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R., and Kreipe, H.

Published
2020

37. Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial

Author

Christgen, M., primary, Harbeck, N., additional, Gluz, O., additional, Raap, M., additional, Christgen, H., additional, Clemens, M., additional, Malter, W., additional, Nuding, B., additional, Aktas, B., additional, Kuemmel, S., additional, Reimer, T., additional, Stefek, A., additional, Krabisch, P., additional, Just, M., additional, Graeser, M., additional, Baehner, R., additional, Wuerstlein, R., additional, Nitz, U., additional, Kates, R., additional, and Kreipe, H., additional

Published
2020
Full Text
View/download PDF

38. LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results

Author

Harbeck, N., primary, Nitz, U., additional, Christgen, M., additional, Kuemmel, S., additional, Braun, M., additional, Schumacher, C., additional, Potenberg, J., additional, Tio, J., additional, Aktas, B., additional, Malter, W., additional, Forstbauer, H., additional, von Schumann, R., additional, Just, M., additional, Jóźwiak, K., additional, Hauptmann, M., additional, Kates, R., additional, Gräser, M., additional, Wuerstlein, R., additional, and Kreipe, H., additional

Published
2020
Full Text
View/download PDF

39. 164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results

Author

Grote, I., primary, Bartels, S., additional, Kandt, L., additional, Bollmann, L., additional, Christgen, H., additional, Gronewold, M., additional, Gluz, O., additional, Nitz, U., additional, Kümmel, S., additional, Braun, M., additional, Aktas, B., additional, Grischke, E-M., additional, Schumacher, C., additional, Lüdtke-Heckenkamp, K., additional, Kates, R., additional, Wuerstlein, R., additional, Gräser, M., additional, Harbeck, N., additional, Christgen, M., additional, and Kreipe, H., additional

Published
2020
Full Text
View/download PDF

44. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Author

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., Walter-Kirst, R., Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., and Walter-Kirst, R.

Abstract

PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULT Of the 3,198 registered patients, 348 (RS <= 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v60.8%; pNO, 58.2% v59.5%; pT1, 57.6% v52.3%; HR positive, 81.4% v82.2%; RS greater than 25 [in H.R-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), de

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results